Pfizer, the world's largest drug company, and Wyeth have sued Daiichi Sankyo-owned Ranbaxy Laboratories in a US court for infringing the patent rights of Wyeth's drug, Rapamune.
An extensive analysis of the available results of companies for the just-concluded fourth quarter shows robust growth in sales and profit, carrying forward the momentum from earlier quarters.
Elder Pharma employs about 3,300 people in India, with about 2,700 professionals in marketing and sales. This recruitment will help Elder Pharma to have one of the largest drug sales force in India, like market leaders such as Cipla, Ranbaxy, Piramal Healthcare and Lupin.
No fewer than 276 new billionaires have entered the list this year.
India Inc's order book doubled in the fourth quarter (January-March) of the last financial year compared, to the year-ago period.
145 companies have paid Rs 125.65 billion (Rs 12,565 crore) as interim dividend for 2009-10
India Inc is expected to post 35-45 per cent rise in net profit in the fourth quarter ended March 31.
Cephalon, a US-based drug maker, has filed a lawsuit against Lupin Ltd and its US subsidiary Lupin Pharmaceuticals for challenging the patents on its sleep disorder drug Nuvigil.
The foreign investors' attraction for India funds seems to be as restrained as in 2009, with only five such funds launched in the first two months of 2010, mobilising $492 million.
Andrew Witty, chief executive of GlaxoSmithKline (GSK), the world's second-largest drug company, was in India this week as part of the dedication of an albandazole manufacturing facility at Nashik to the World Health Organization (WHO)'s global programme to eliminate Lymphatic Filariasis.
A study of 435 companies listed on the Bombay Stock Exchange, which provide their capital-employed data on a quarterly basis, shows capex grew by a meagre 3.4 per cent in the nine months ending December 2009, compared to the level in March 2009.
If most of the top 10 Indian drug companies were less than Rs 500-crore (Rs 5-billion) turnover ones a decade earlier and were focused only on domestic business, now they are companies with annual businesses ranging from Rs 2,000-Rs 6,000 crore (Rs 20-60 billion) and with operations spanning 60-100 countries and employing 3,000-5,000 people.
Corporate India will have to shell out an additional Rs 21,000 crore (Rs 210 billion) if the 2010-11 Budget increases the excise duty by 2 per cent.
An analysis of the growth rate of 15 leading drug companies for the third quarter of 2008-09 show excellent performances in domestic turf have been often marred by the poor show of their acquired assets.
The deal size could be in excess of Rs 2,000 crore, though this could not be verified. Sivasankaran had invested close to Rs 1,800 crore in 2007 to take a 41 per cent stake in Aamby Valley. The Sahara Group is the majority investor, with a 51 per cent stake.
In this emerging trend, doctors are joining hands with venture capitalists, drug firms and medical equipment vendors to set up advanced medical care facilities at low costs.
India Inc as a whole has recorded a 62 per cent rise in net profit and 310 basis point rise in margins.
This metro line would be a 33.65-km rail link between Bangalore City Centre and Bangalore International Airport.
It has 150 research and development locations in over 30 countries around the world, employing over 32,300 people.
the early 1980s, multinationals set up R&D units in India to make use of the low costs and huge talent pool.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances